Tokai Pharmaceuticals Inc  

(Public, NASDAQ:TKAI)   Watch this stock  
Find more results for Joseph McBride
11.78
-0.07 (-0.63%)
Real-time:   1:33PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.72 - 11.99
52 week 9.67 - 30.00
Open 11.84
Vol / Avg. 24,931.00/86,761.00
Mkt cap 266.84M
P/E     -
Div/yield     -
EPS -1.43
Shares 22.41M
Beta     -
Inst. own 28%
May 13, 2015
Tokai Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 12, 2015
Q1 2015 Tokai Pharmaceuticals Inc Earnings Release
Apr 15, 2015
Tokai Pharmaceuticals Inc at Needham Healthcare Conference
Mar 12, 2015
Q4 2014 Tokai Pharmaceuticals Inc Earnings Release
Mar 4, 2015
Tokai Pharmaceuticals Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.04% -33.27%
Return on average equity -54.72% -96.60%
Employees 17 -
CDP Score - -

Address

1 Broadway Fl 14th
CAMBRIDGE, MA 02142-1187
United States - Map
+1-617-2254348 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Tokai Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing therapies for the treatment of prostate cancer and other hormonally-driven diseases. The Company’s drug candidate, Galeterone, is a multi-targeted, oral small molecule drug candidate for the treatment of prostate cancer that disrupts androgen receptor signaling through three mechanisms of action. Galeterone acts by disrupting the androgen receptor signaling pathway, which is a pathway that drives prostate cancer growth. The Company has a drug discovery program, ARDA (Androgen Receptor Modulation Optimized for Response). ARDA is focused on the identification and evaluation of compounds with potent androgen receptor degradation activity targeted to patients with androgen receptor signaling diseases, including prostate cancer.

Officers and directors

Lee H. Kalowski Chief Financial Officer
Age: 34
Bio & Compensation  - Reuters
John S. McBride Chief Operating Officer
Age: 63
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Head - Research and Development and Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Seth L. Harrison M.D. Independent Chairman of the Board
Age: 54
Bio & Compensation  - Reuters
Jodie Pope Morrison President, Chief Executive Officer, Director
Age: 39
Bio & Compensation  - Reuters
Cheryl L. Cohen Director
Age: 49
Bio & Compensation  - Reuters
Timothy Joseph Barberich Independent Director
Age: 67
Bio & Compensation  - Reuters
Stephen Buckley Jr. Independent Director
Age: 65
Bio & Compensation  - Reuters
David A. Kessler M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Joseph A. Yanchik III Independent Director
Age: 51
Bio & Compensation  - Reuters